Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mertiatide→

Mertiatide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
66516-09-4
Molecular formula
C8H13N3O5S
Molecular weight
263.27 g/mol
Drug class
Technetium-99m renal radiopharmaceuticaltubular secretion imaging agent
Mechanism of action
Technetium-99m mertiatide (MAG3) is highly protein-bound but reversibly so, and is rapidly cleared from blood by renal tubular secretion and glomerular filtration. Dynamic renal uptake and excretion are measured by scintigraphy to assess perfusion, function and urinary drainage.
Indications / reported uses
  • Renal scintigraphy to evaluate congenital or acquired renal abnormalities, renal failure, urinary tract obstruction and renal calculi in adults and children.
  • Provides information on overall and split renal function, renal angiograms and renogram curves for whole kidney and renal cortex.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0571c18b-1d5e-47bd-bddf-54d74ce1b442 · https://www.ndf.gov.sg/about-drugs/product-information/sin06741p/ · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=D017263 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Technetium-99m renal radiopharmaceutical; tubular secretion imaging agent

Mechanism of action

Technetium-99m mertiatide (MAG3) is highly protein-bound but reversibly so, and is rapidly cleared from blood by renal tubular secretion and glomerular filtration. Dynamic renal uptake and excretion are measured by scintigraphy to assess perfusion, function and urinary drainage.

General use cases

  • Renal scintigraphy to evaluate congenital or acquired renal abnormalities, renal failure, urinary tract obstruction and renal calculi in adults and children.
  • Provides information on overall and split renal function, renal angiograms and renogram curves for whole kidney and renal cortex.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Mertiatide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mertiatide Permitted Daily Exposure (PDE) report (the Mertiatide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mertiatide Occupational Exposure Limit (OEL) report (the Mertiatide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.